🇺🇸 Nanoliposomal Irinotecan in United States
59 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 59
Most-reported reactions
- Diarrhoea — 9 reports (15.25%)
- Nausea — 9 reports (15.25%)
- Pyrexia — 7 reports (11.86%)
- Disease Progression — 6 reports (10.17%)
- Vomiting — 6 reports (10.17%)
- Asthenia — 5 reports (8.47%)
- Sepsis — 5 reports (8.47%)
- Abdominal Pain — 4 reports (6.78%)
- Acute Kidney Injury — 4 reports (6.78%)
- Dehydration — 4 reports (6.78%)
Frequently asked questions
Is Nanoliposomal Irinotecan approved in United States?
Nanoliposomal Irinotecan does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Nanoliposomal Irinotecan in United States?
PharmaEngine is the originator. The local marketing authorisation holder may differ — check the official source linked above.